var data={"title":"Glucagon: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Glucagon: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6268?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=glucagon-drug-information\" class=\"drug drug_general\">see &quot;Glucagon: Drug information&quot;</a> and <a href=\"topic.htm?path=glucagon-patient-drug-information\" class=\"drug drug_patient\">see &quot;Glucagon: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176479\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GlucaGen Diagnostic;</li>\n      <li>GlucaGen HypoKit;</li>\n      <li>Glucagon Emergency</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14733086\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>GlucaGen;</li>\n      <li>GlucaGen HypoKit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058929\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihypoglycemic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442577\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypoglycemia, persistent:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM, IV, SubQ: 0.02-0.2 mg/kg/dose (maximum dose: 1 mg), may repeat dose in 20 minutes if needed (Hawdon, 1993; Mehta, 1987); <b>Note:</b> Wide variance in doses exists between manufacturer&rsquo;s labeling and published case reports. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous IV infusion: 1 mg infused over 24 hours; doses &gt;0.02 mg/kg/<b>hour</b> did not produce additional benefit; dosing based on a retrospective observation of 55 newborns (GA: 24-41 weeks) with hypoglycemia due to multiple causes (Miralles, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Congenital hyperinsulinism; hyperinsulinemic hypoglycemia: </b> Continuous IV infusion: 0.005-0.02 mg/kg/<b>hour</b>; some centers use a lower dose (0.001 mg/kg/<b>hour</b>) in combination with octreotide (Aynsley-Green, 2000; Hussain, 2004, Kapoor, 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058923\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=glucagon-drug-information\" class=\"drug drug_general\">see &quot;Glucagon: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypoglycemia, severe; treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Weight-directed dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling: Infants, Children, or Adolescents weighing &lt;20 kg: Glucagon: IM, IV, SubQ: 0.02-0.03 mg/kg; maximum dose: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AAP: IM, IV, SubQ: 0.03 mg/kg; maximum dose: 1 mg (Hegenbarth, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IDF-ISPAD: IM, SubQ: 0.01-0.03 mg/kg; maximum dose dependent on age: &lt;12 years: 0.5 mg; &ge;12 years: 1 mg (IDF-ISPAD, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fixed dosing; age-directed:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: GlucaGen: IM, IV, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;6 years: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;6 years: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IM, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IDF-ISPAD (IDF-ISPAD, 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &lt;12 years: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &ge;12 years: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CDA (Canadian Diabetes Association, 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &le;5 years: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &gt;5 years: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fixed dosing; weight-directed:</i> Infants, Children, and Adolescents: Manufacturer's labeling: IM, IV, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Glucagon: Patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;20 kg: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;20 kg: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GlucaGen: Patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;25 kg: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;25 kg: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoglycemia, prevention during illness (fixed dosing, mini-dose):</b> Limited data available (Haymond, 2001; IDF-ISPAD, 2011): SubQ: <b>Note:</b> These doses are lower than hypoglycemia treatment doses and have been shown to prevent hypoglycemia for several hours during hypoglycemia-associated illness (eg, gastroenteritis, nausea/vomiting). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: 0.02 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 2-15 years: 0.01 mg per year of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &gt;15 years: 0.15 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Beta-blocker or calcium channel blocker toxicity/overdose:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: Limited data available (Hegenbarth, 2008): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 0.03-0.15 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 0.07 mg/kg/hour; maximum rate: 5 mg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents [Hegenbarth, 2008; PALS guidelines (Kleinman, 2010)]: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 5-10 mg over several minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 1-5 mg/hour</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoglycemia:</b> IM, IV, SubQ: 1 mg; may repeat in 20 minutes as needed; <b>Note:</b> IV dextrose should be administered as soon as it is available; if patient fails to respond to glucagon, IV dextrose must be given.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Beta-blocker- or calcium channel blocker-induced myocardial depression (with or without hypotension) unresponsive to standard measures:</b> IV: 3-10 mg (or 0.05-0.15 mg/kg) bolus followed by an infusion of 3-5 mg/hour (or 0.05-0.1 mg/kg/hour); titrate infusion rate to achieve adequate hemodynamic response (ACLS, 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic aid:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 1-2 mg 10 minutes prior to gastrointestinal procedure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.25-2 mg 10 minutes prior to gastrointestinal procedure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in renal impairment:</b> There are no dosage adjustment provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in hepatic impairment:</b> There are no dosage adjustment provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112191\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112192\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176481\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=glucagon-drug-information\" class=\"drug drug_general\">see &quot;Glucagon: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Diagnostic aid:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Relaxation of stomach, duodenal bulb, duodenum, and small bowel:</i></p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IM: 1 mg</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IV: 0.2 to 0.5 mg</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <i>Relaxation of colon:</i></p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IM: 1 to 2 mg</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IV: 0.5 to 0.75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypoglycemia:</b> IM, IV, SubQ: 1 mg; may repeat in 15 minutes as needed. <b>Note:</b>  IV dextrose should be administered as soon as it is available; if patient fails to respond to glucagon, IV dextrose must be given. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anaphylactic reaction (refractory) in patients on beta-blocker therapy (off-label use):</b>  IV: Initial:  1 to 5 mg; followed by an infusion of 5 to 15 mcg/minute; titrate the infusion rate to achieve an adequate clinical response (Lieberman 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Beta-blocker- or calcium channel blocker-induced myocardial depression (with or without hypotension) unresponsive to standard measures (off-label use; AHA [Vanden Hoek 2010]; Bailey 2003): </b>IV: 3 to 10 mg (or 0.05 to 0.15 mg/kg) bolus followed by an infusion of 3 to 5 mg/hour (or 0.05 to 0.1 mg/kg/hour); titrate infusion rate to achieve adequate clinical response (AHA [Vanden Hoek 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991850\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989145\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176459\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucagon Emergency: 1 mg [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GlucaGen Diagnostic: 1 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GlucaGen HypoKit: 1 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176444\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058933\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral May administer IM, IV, or SubQ. When treating beta-blocker/calcium channel blocker toxicity, initial loading dose (bolus) should be administered over 3 to 5 minutes; may also administer as a continuous IV infusion; ensure adequate supply available to continue therapy (AHA [Vanden Hoek] 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Mini-dose: Inject subcutaneously using an insulin syringe (U-100); 1 unit on the syringe provides 0.01 mg of glucagon (Haymond 2001; IDF-ISPAD 2011) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176475\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution, store at 20&deg;C to 25&deg;C (69&deg;F to 77&deg;F) for up to 24 months. Do not freeze. Protect from light. Use reconstituted solution immediately; discard unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058932\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of severe hypoglycemia [FDA approved in pediatric patients (age not specified) and adults]; diagnostic aid in the radiologic examination of GI tract to temporarily inhibit GI tract movement (FDA approved in adults); has also been used for prevention of hypoglycemia during illness and management of beta-blocker or calcium channel blocker toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176517\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension, hypotension (up to 2 hours after GI procedures), increased blood pressure, increased pulse, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting (high incidence with rapid administration of high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hypoglycemia, hypoglycemic coma, respiratory distress, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176465\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to glucagon, lactose, or any component of the formulation; pheochromocytoma; insulinoma; glucagonoma (excluding GlucaGen)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176448\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Allergic reactions including skin rash and anaphylactic shock (with hypotension and respiratory difficulties) have been reported; reactions have generally been associated with endoscopic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; levels of glucose stores in liver may be decreased. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac disease: Use with caution in patients with cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Chronic hypoglycemia: Use with caution in patients with chronic hypoglycemia; levels of glucose stores in liver may be decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use caution if using as diagnostic aid in patients with diabetes on insulin; may cause hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucagonoma: Use with caution in patients with glucagonoma. The use of glucagon is contraindicated in patients with this condition (excluding GlucaGen).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Insulinoma: Exogenous glucagon may cause an initial rise in blood glucose followed by rebound hypoglycemia. The use of glucagon is contraindicated in patients with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pheochromocytoma: Exogenous glucagon may cause the release of catecholamines, resulting in an increase in blood pressure. The use of glucagon is contraindicated in patients with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Starvation/fasting: Use caution with prolonged fasting and/or starvation; levels of glucose stores in liver may be decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lactose: May contain lactose; avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Insulin or sulfonylurea overdose: Patients with hypoglycemia should immediately be treated with dextrose. If IV access cannot be established or if dextrose is not available, glucagon may be considered as alternative acute treatment until dextrose can be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary hypoglycemia: Supplemental carbohydrates should be given to patients who respond to glucagon for severe hypoglycemia to prevent secondary hypoglycemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25881788\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Glucagon depletes glycogen stores; supplemental carbohydrates (which may include IV dextrose) should be administered as soon as physically possible. If a patient fails to respond to glucagon, IV dextrose must be administered. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299406\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176453\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13335&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indomethacin: May diminish the therapeutic effect of Glucagon.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Glucagon may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176477\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Glucagon depletes glycogen stores.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176455\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13882222\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058928\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood glucose, blood pressure, ECG, heart rate, mentation; in pediatric patients when used for hypoglycemia prevention (mini-doses), monitor blood glucose [every 30 minutes for the first hours and then at least hourly (or more often if appropriate)] (Haymond, 2001)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176447\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Stimulates adenylate cyclase to produce increased cyclic AMP, which promotes hepatic glycogenolysis and gluconeogenesis, causing a raise in blood glucose levels; antihypoglycemic effect requires preexisting hepatic glycogen stores. Extra hepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176464\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blood glucose levels: Peak effect: IV: 5 to 20 minutes; IM: 30 minutes; SubQ: 30 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GI relaxation: IV: 45 seconds; IM: 4 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Glucose elevation: IV, IM, SubQ: 60 to 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GI relaxation: IV: 9 to 25 minutes; IM: 12 to 32 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.25 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic; some inactivation occurring renally and in plasma </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, plasma: IV: 8 to 18 minutes; IM (apparent): 26 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM: ~10 to 12.5 minutes; SubQ: 20 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524623\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Glucagon Emergency Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $336.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GlucaGen Diagnostic Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $205.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GlucaGen HypoKit Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $325.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Glucagon HCl (Diagnostic) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $204.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176469\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Garcon (KR);</li>\n      <li>Glucagen (AE, AR, AU, BB, BE, BH, BR, CH, CL, CO, CU, CY, DE, DK, EC, ES, FR, GR, HK, IE, IN, IT, JO, KW, LB, LK, MY, NZ, PL, PY, SA, TH, UY, ZA);</li>\n      <li>GlucaGen (AT, FI, GB, HR, HU, IE, IL, IS, LT, LU, LV, MT, NL, PT, QA, SG, SI, SK, TR, VN);</li>\n      <li>Glucagen G (JP);</li>\n      <li>Glucagen Novo (HK);</li>\n      <li>Glucagon Novo Nordisk (SE);</li>\n      <li>R-Glucagon Lilly (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association. Standards of medical care in diabetes-2014. <i>Diabetes Care</i>. 2014;37 Suppl 1:S14-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/24357209/pubmed\" target=\"_blank\" id=\"24357209\">24357209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aynsley-Green A, Hussain K, Hall J, et al, &quot;Practical Management of Hyperinsulinism in Infancy,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2000, 82(2):98-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/10685981/pubmed\" target=\"_blank\" id=\"10685981\">10685981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Type 1 diabetes in children and adolescents. <i>Can J Diabetes</i> 2013;37:S153-162.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S640-656.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hawdon JM, Aynsley-Green A, and Ward Platt MP, &quot;Neonatal Blood Glucose Concentrations: Metabolic Effects of Intravenous Glucagon and Intragastric Medium Chain Triglyceride,&quot; <i>Arch Dis Child</i>, 1993, 68(3 Spec No):255-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/8466259/pubmed\" target=\"_blank\" id=\"8466259\">8466259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. <i>Diabetes Care</i>. 2001;24(4):643-645.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/11315823/pubmed\" target=\"_blank\" id=\"11315823\">11315823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hussain K and Aynsley-Green A, &quot;Hyperinsulinaemic Hypoglycaemia in Preterm Neonates,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2004, 89(1):65-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/14711860/pubmed\" target=\"_blank\" id=\"14711860\">14711860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IDF/ISPAD. Global guideline for diabetes in childhood and adolescence, 2013. Available at http://www.idf.org/global-idfispad-guideline-diabetes-childhood-and-adolescence. Date accessed:  April 14, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kapoor RR, Flanagan SE, James C, et al, &quot;Hyperinsulinaemic Hypoglycaemia,&quot; <i>Arch Dis Child</i>, 2009, 94(6):450-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/19193661/pubmed\" target=\"_blank\" id=\"19193661\">19193661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.<i>Circulation</i>. 2010;122(18 Suppl 3):S876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Love JN, Sachdeva DK, Bessman ES, Curtis LA, Howell JM. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia.<i> Chest</i>. 1998;114(1):323-326.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehta A, Wootton R, Cheng KN, et al, &quot;Effect of Diazoxide or Glucagon on Hepatic Glucose Production Rate During Extreme Neonatal Hypoglycaemia,&quot;<i> Arch Dis Child</i>, 1987, 62(9):924-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/3314727/pubmed\" target=\"_blank\" id=\"3314727\">3314727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miralles RE, Lodha A, Perlman M, et al, &quot;Experience With Intravenous Glucagon Infusions as a Treatment for Resistant Neonatal Hypoglycemia,&quot; <i>Arch Pediatr Adolesc Med</i>, 2002, 156(10):999-1004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/12361445/pubmed\" target=\"_blank\" id=\"12361445\">12361445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S829-861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-pediatric-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13335 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F176479\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14733086\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058929\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442577\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1058923\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112191\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112192\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F176481\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991850\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989145\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F176459\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F176444\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058933\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F176475\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058932\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F176517\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F176465\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F176448\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25881788\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299406\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F176453\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F176477\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F176455\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13882222\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058928\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F176447\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F176464\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524623\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F176469\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13335|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=glucagon-drug-information\" class=\"drug drug_general\">Glucagon: Drug information</a></li><li><a href=\"topic.htm?path=glucagon-patient-drug-information\" class=\"drug drug_patient\">Glucagon: Patient drug information</a></li></ul></div></div>","javascript":null}